Mucosal protective agents prevent exacerbation of NSAID-induced small intestinal lesions caused by antisecretory drugs in rats

Journal of Pharmacology and Experimental Therapeutics

Volumn 348, Issue 2, 2014, Pages 227-235

  Satoh, Hiroshi ^a   Amagase, Kikuko ^a   Takeuchi, Koji ^a  

^a KYOTO PHARMACEUTICAL UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

DICLOFENAC; HISTAMINE H2 RECEPTOR ANTAGONIST; IRSOGLADINE MALEATE; MISOPROSTOL; MUCIN; OMEPRAZOLE; PROTON PUMP INHIBITOR; RANITIDINE; REBAMIPIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; DISEASE EXACERBATION; DRUG MEGADOSE; INTESTINE MOTILITY; INTESTINE MUCUS; LOW DRUG DOSE; MALE; MONOTHERAPY; MUCUS; NONHUMAN; PRIORITY JOURNAL; RAT; SMALL INTESTINE DISEASE;

EID: 84893052315     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.113.208991     Document Type: Article

References (46)

1. Akagi M, Amagase K, Murakami T, and Takeuchi K (2013) Irsogladine: overview of the mechanisms of mucosal protective and healing-promoting actions in the gastrointestinal tract. Curr Pharm Des 19:106-114.
2. Arakawa T, Higuchi K, Fujiwara Y, Watanabe T, Tominaga K, Sasaki E, Oshitani N, Yoshikawa T, and Tarnawski AS (2005) 15th anniversary of rebamipide: looking ahead to the new mechanisms and new applications. Dig Dis Sci 50 (Suppl 1): S3-S11.
3. Bjarnason I, Smethurst P, Fenn CG, Lee CE, Menzies IS, and Levi AJ (1989) Misoprostol reduces indomethacin-induced changes in human small intestinal permeability. Dig Dis Sci 34:407-411.
4. Cryer B, Bhatt DL, Lanza FL, Dong JF, Lichtenberger LM, and Marathi UK (2011) Low-dose aspirin-induced ulceration is attenuated by aspirin- phosphatidylcholine: a randomized clinical trial. Am J Gastroenterol 106:272-277.
5. Fujimori S, Seo T, Gudis K, Ehara A, Kobayashi T, Mitsui K, Yonezawa M, Tanaka S, Tatsuguchi A, and Sakamoto C (2009) Prevention of nonsteroidal antiinflammatory drug-induced small-intestinal injury by prostaglandin: a pilot randomized controlled trial evaluated by capsule endoscopy. Gastrointest Endosc 69: 1339-1346.
6. Goldstein JL, Eisen GM, Lewis B, Gralnek IM, Zlotnick S, and Fort JG; Investigators (2005) Video capsule endoscopy to prospectively assess small bowel injury with celecoxib, naproxen plus omeprazole, and placebo. Clin Gastroenterol Hepatol 3: 133-141.
7. Graham DY, Opekun AR, Willingham FF, and Qureshi WA (2005) Visible smallintestinal mucosal injury in chronic NSAID users. Clin Gastroenterol Hepatol 3: 55-59.
8. Hiraishi H, Haruma K, Miwa H, and Goto H (2010) Clinical trial: irsogladine maleate, a mucosal protective drug, accelerates gastric ulcer healing after treatment for eradication of Helicobacter pylori infection-the results of a multicentre, double-blind, randomized clinical trial (IMPACT study). Aliment Pharmacol Ther 31:824-833.
9. Iijima K, Ichikawa T, Okada S, Ogawa M, Koike T, Ohara S, and Shimosegawa T (2009) Rebamipide, a cytoprotective drug, increases gastric mucus secretion in human: evaluations with endoscopic gastrin test. Dig Dis Sci 54:1500-1507.
10. Ishihara K, Komuro Y, Nishiyama N, Yamasaki K, and Hotta K (1992) Effect of rebamipide on mucus secretion by endogenous prostaglandin-independent mechanism in rat gastric mucosa. Arzneimittelforschung 42:1462-1466.
11. Kamei K, Kubo Y, Kato N, Hatazawa R, Amagase K, and Takeuchi K (2008) Prophylactic effect of irsogladine maleate against indomethacin-induced small intestinal lesions in rats. Dig Dis Sci 53:2657-2666.
12. Kunikata T, Tanaka A, Miyazawa T, Kato S, and Takeuchi K (2002) 16,16-Dimethyl prostaglandin E2 inhibits indomethacin-induced small intestinal lesions through EP3 and EP4 receptors. Dig Dis Sci 47:894-904.
13. Kuramoto T, Umegaki E, Nouda S, Narabayashi K, Kojima Y, Yoda Y, Ishida K, Kawakami K, Abe Y, and Takeuchi T, et al. (2013) Preventive effect of irsogladine or omeprazole on non-steroidal anti-inflammatory drug-induced esophagitis, peptic ulcers, and small intestinal lesions in humans, a prospective randomized controlled study. BMC Gastroenterol 13:85.
14. Kyoi T, Oka M, Noda K, and Ukai Y (2004) Phosphodiesterase inhibition by a gastroprotective agent irsogladine: preferential blockade of cAMP hydrolysis. Life Sci 75:1833-1842.
15. Leandro G, Pilotto A, Franceschi M, Bertin T, Lichino E, and Di Mario F (2001) Prevention of acute NSAID-related gastroduodenal damage: a meta-analysis of controlled clinical trials. Dig Dis Sci 46:1924-1936.
16. Lichtenberger LM, Barron M, and Marathi U (2009) Association of phosphatidylcholine and NSAIDs as a novel strategy to reduce gastrointestinal toxicity. Drugs Today (Barc) 45:877-890.
17. Maiden L, Thjodleifsson B, Theodors A, Gonzalez J, and Bjarnason I (2005) A quantitative analysis of NSAID-induced small bowel pathology by capsule enteroscopy. Gastroenterology 128:1172-1178.
18. Matsumoto T, Kudo T, Esaki M, Yano T, Yamamoto H, Sakamoto C, Goto H, Nakase H, Tanaka S, and Matsui T, et al. (2008) Prevalence of non-steroidal antiinflammatory drug-induced enteropathy determined by double-balloon endoscopy: a Japanese multicenter study. Scand J Gastroenterol 43:490-496.
19. Mizoguchi H, Ogawa Y, Kanatsu K, Tanaka A, Kato S, and Takeuchi K (2001) Protective effect of rebamipide on indomethacin-induced intestinal damage in rats. J Gastroenterol Hepatol 16:1112-1119.
20. Mizukami K, Murakami K, Hirashita Y, Hisamatsu A, Ogawa R, Uchida M, Nakagawa Y, Okimoto T, Kodama M, and Fujioka T (2012) Efficacy of rebamipide for low-dose aspirin-related gastrointestinal symptoms. J Clin Biochem Nutr 51: 216-220.
21. Naito Y and Yoshikawa T (2010) Rebamipide: a gastrointestinal protective drug with pleiotropic activities. Expert Rev Gastroenterol Hepatol 4:261-270.
22. Niwa Y, Nakamura M, Ohmiya N, Maeda O, Ando T, Itoh A, Hirooka Y, and Goto H (2008) Efficacy of rebamipide for diclofenac-induced small-intestinal mucosal injuries in healthy subjects: a prospective, randomized, double-blinded, placebocontrolled, cross-over study. J Gastroenterol 43:270-276.
23. Peura DA (2004) Prevention of nonsteroidal anti-inflammatory drug-associated gastrointestinal symptoms and ulcer complications. Am J Med 117 (Suppl 5A):63S-71S.
24. Sakurai K, Sasabe H, Koga T, and Konishi T (2004) Mechanism of hydroxyl radical scavenging by rebamipide: identification of mono-hydroxylated rebamipide as a major reaction product. Free Radic Res 38:487-494.
25. Satoh H (2010) Role of dietary fiber in formation and prevention of small intestinal ulcers induced by nonsteroidal anti-inflammatory drug. Curr Pharm Des 16:1209-1213.
26. Satoh H, Amagase K, and Takeuchi K (2012) Exacerbation of nonsteroidal antiinflammatory drug-induced small intestinal lesions by antisecretory drugs in rats: the role of intestinal motility. J Pharmacol Exp Ther 343:270-277.
27. Satoh H, Hara T, Murakawa D, Matsuura M, and Takata K (2010) Soluble dietary fiber protects against nonsteroidal anti-inflammatory drug-induced damage to the small intestine in cats. Dig Dis Sci 55:1264-1271.
28. Satoh H, Shiotani S, Otsuka N, Hatao K, and Nishimura S (2009) Role of dietary fibres, intestinal hypermotility and leukotrienes in the pathogenesis of NSAIDinduced small intestinal ulcers in cats. Gut 58:1590-1596.
29. Satoh H and Takeuchi K (2012) Management of NSAID/aspirin-induced small intestinal damage by GI-sparing NSAIDs, anti-ulcer drugs and food constituents. Curr Med Chem 19:82-89.
30. Scarpignato C and Hunt RH (2010) Nonsteroidal antiinflammatory drug-related injury to the gastrointestinal tract: clinical picture, pathogenesis, and prevention. Gastroenterol Clin North Am 39:433-464.
31. Sugano K, Matsumoto Y, Itabashi T, Abe S, Sakaki N, Ashida K, Mizokami Y, Chiba T, Matsui S, and Kanto T, et al. (2011) Lansoprazole for secondary prevention of gastric or duodenal ulcers associated with long-term low-dose aspirin therapy: results of a prospective, multicenter, double-blind, randomized, double-dummy, active-controlled trial. J Gastroenterol 46:724-735.
32. Takeuchi K, Miyazawa T, Tanaka A, Kato S, and Kunikata T (2002) Pathogenic importance of intestinal hypermotility in NSAID-induced small intestinal damage in rats. Digestion 66:30-41.
33. Takeuchi K, Tanaka A, Kato S, Amagase K, and Satoh H (2010) Roles of COX inhibition in pathogenesis of NSAID-induced small intestinal damage. Clin Chim Acta 411:459-466.
34. Uchida M, Tabusa F, Komatsu M, Morita S, Kanbe T, and Nakagawa K (1985) Studies on 2(1H)-quinolinone derivatives as gastric antiulcer active agents. 2-(4-Chlorobenzoylamino)-3-[2(1H)-quinolinon-4-yl]propi oni c acid and related compounds. Chem Pharm Bull (Tokyo) 33:3775-3786.
35. Ueda F, Aratani S, Mimura K, Kimura K, Nomura A, and Enomoto H (1984a) Effect of 2,4-diamino-6-(2,5-dichlorophenyl)-s-triazine maleate (MN-1695) on gastric ulcers and gastric secretion in experimental animals. Arzneimittelforschung 34: 474-477.
36. Ueda F, Aratani S, Mimura K, Kimura K, Nomura A, and Enomoto H (1984b) Effect of 2,4-diamino-6-(2,5-dichlorophenyl)-s-triazine maleate (MN-1695) on gastric mucosal damage induced by various necrotizing agents in rats. Arzneimittelforschung 34:478-484.
37. Ueda F, Ban K, and Ishima T (1995) Irsogladine activates gap-junctional intercellular communication through M1 muscarinic acetylcholine receptor. J Pharmacol Exp Ther 274:815-819.
38. Wallace JL (2013) Mechanisms, prevention and clinical implications of nonsteroidal anti-inflammatory drug-enteropathy. World J Gastroenterol 19:1861-1876.
39. Wallace JL, Caliendo G, Santagada V, and Cirino G (2010) Markedly reduced toxicity of a hydrogen sulphide-releasing derivative of naproxen (ATB-346). Br J Pharmacol 159:1236-1246.
40. Wallace JL and Del Soldato P (2003) The therapeutic potential of NO-NSAIDs. Fundam Clin Pharmacol 17:11-20.
41. Wallace JL, Syer S, Denou E, de Palma G, Vong L, McKnight W, Jury J, Bolla M, Bercik P, and Collins SM, et al. (2011) Proton pump inhibitors exacerbate NSAIDinduced small intestinal injury by inducing dysbiosis. Gastroenterology 141: 1314-1322, e1-e5.
42. Watanabe T, Sugimori S, Kameda N, Machida H, Okazaki H, Tanigawa T, Watanabe K, Tominaga K, Fujiwara Y, and Oshitani N, et al. (2008) Small bowel injury by low-dose enteric-coated aspirin and treatment with misoprostol: a pilot study. Clin Gastroenterol Hepatol 6:1279-1282.
43. Yamasaki K, Kanbe T, Chijiwa T, Ishiyama H, and Morita S (1987) Gastric mucosal protection by OPC-12759, a novel antiulcer compound, in the rat. Eur J Pharmacol 142:23-29.
44. Yeomans ND, Svedberg LE, and Naesdal J (2006) Is ranitidine therapy sufficient for healing peptic ulcers associated with non-steroidal anti-inflammatory drug use? Int J Clin Pract 60:1401-1407.
45. Yoda Y, Amagase K, Kato S, Tokioka S, Murano M, Kakimoto K, Nishio H, Umegaki E, Takeuchi K, and Higuchi K (2010) Prevention by lansoprazole, a proton pump inhibitor, of indomethacin-induced small intestinal ulceration in rats through induction of heme oxygenase-1. J Physiol Pharmacol 61:287-294.
46. Yoshikawa T, Naito Y, Tanigawa T, and Kondo M (1993) Free radical scavenging activity of the novel anti-ulcer agent rebamipide studied by electron spin resonance. Arzneimittelforschung 43:363-366.